AR034396A1 - Compuestos 4-(1r-4-piperidilen)-4h-benzo[4,5]ciclohepta[1,2]-tiofeno-1-a y sus isomeros opticamente activos, un metodo para su sintesis y el uso de dichos compuestos para la manufactura de un medicamento - Google Patents

Compuestos 4-(1r-4-piperidilen)-4h-benzo[4,5]ciclohepta[1,2]-tiofeno-1-a y sus isomeros opticamente activos, un metodo para su sintesis y el uso de dichos compuestos para la manufactura de un medicamento

Info

Publication number
AR034396A1
AR034396A1 ARP000104790A ARP000104790A AR034396A1 AR 034396 A1 AR034396 A1 AR 034396A1 AR P000104790 A ARP000104790 A AR P000104790A AR P000104790 A ARP000104790 A AR P000104790A AR 034396 A1 AR034396 A1 AR 034396A1
Authority
AR
Argentina
Prior art keywords
compounds
ketotifen
norketotifen
hydroxy
compound
Prior art date
Application number
ARP000104790A
Other languages
English (en)
Original Assignee
Bridge Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bridge Pharma Inc filed Critical Bridge Pharma Inc
Publication of AR034396A1 publication Critical patent/AR034396A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto 4-(1R-4-piperidilen)-4H-benzo[4,5]ciclohepta[1,2]-tiofeno-1-A, que comprende la estructura (1) en la cual A es -CO- o -CHPH- y R es CH3 o H y las formas estereoquímicamente isoméricas y diastereómeros del mismo, con las siguientes condiciones: que A no sea -CO- cuando R es CH3; que A no sea -CO- cuando R es H si el compuesto es un racemato, que A no sea -CHOH- cuando R es CH3 si el compuesto es un racemato; que A no sea -CHOH- cuando R es H si el compuesto es un racemato; y sales y solvatos farmacéuticamente aceptables del mismo. Se encontró que el norketotifeno racémico, el 10-hidroxi-ketotifeno racémico, el 10-hidroxi-norketotifeno racémico y los isómeros ópticamente activos del ketotifeno, norketotifeno, 10-hidroxi-ketotifeno y 10-hidroxi-norketotifeno tenía efectos antialérgicos y antiinflamatorios careciendo, sin embargo, de los serios efectos colaterales limitantes de la dosis del ketotifeno. Además se describe un método para la síntesis de dichos compuestos y el uso de los mismos para la manufactura de un medicamento para prevenir o tratar una enfermedad seleccionada entre el grupo que consiste en trastornos respiratorios, trastornos alérgicos, trastornos cutáneos, trastornos gastrointestinales y trastornos oculares.
ARP000104790A 1999-09-13 2000-09-13 Compuestos 4-(1r-4-piperidilen)-4h-benzo[4,5]ciclohepta[1,2]-tiofeno-1-a y sus isomeros opticamente activos, un metodo para su sintesis y el uso de dichos compuestos para la manufactura de un medicamento AR034396A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15356699P 1999-09-13 1999-09-13
US19790500P 2000-04-15 2000-04-15
US19798500P 2000-04-15 2000-04-15
US19790600P 2000-04-15 2000-04-15
US19736300P 2000-04-15 2000-04-15

Publications (1)

Publication Number Publication Date
AR034396A1 true AR034396A1 (es) 2004-02-25

Family

ID=27538454

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104790A AR034396A1 (es) 1999-09-13 2000-09-13 Compuestos 4-(1r-4-piperidilen)-4h-benzo[4,5]ciclohepta[1,2]-tiofeno-1-a y sus isomeros opticamente activos, un metodo para su sintesis y el uso de dichos compuestos para la manufactura de un medicamento

Country Status (18)

Country Link
US (3) US7226934B1 (es)
EP (1) EP1218007B1 (es)
JP (1) JP5116928B2 (es)
CN (1) CN1391475A (es)
AR (1) AR034396A1 (es)
AT (1) ATE516804T1 (es)
AU (1) AU782816B2 (es)
BR (1) BR0013935A (es)
CA (1) CA2383222C (es)
CY (1) CY1112605T1 (es)
DK (1) DK1218007T3 (es)
HU (1) HUP0202671A3 (es)
IL (2) IL148368A0 (es)
MX (1) MXPA02002658A (es)
MY (1) MY134888A (es)
PL (1) PL353586A1 (es)
PT (1) PT1218007E (es)
WO (1) WO2001019367A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL353586A1 (en) * 1999-09-13 2003-12-01 Bridge Pharma, Inc.Bridge Pharma, Inc. Optically active isomers of ketotifen and therapeutically active metabolites thereof
WO2008153761A1 (en) * 2007-05-23 2008-12-18 Mastcell Pharmaceuticals, Inc. Methods
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
CA2727847C (en) 2008-06-13 2014-08-05 Case Western Reserve University Compositions and methods for treating corneal inflammation
US8741930B2 (en) * 2008-10-24 2014-06-03 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
WO2010059894A1 (en) * 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
JP2012520880A (ja) * 2009-03-17 2012-09-10 アーシエックス セラピューティックス, インコーポレイテッド ケトチフェンの眼科用製剤および使用方法
WO2013000406A1 (zh) 2011-06-28 2013-01-03 Lin Tongjun 抗-变态反应的苯并环庚并噻吩衍生物
US8778971B2 (en) 2012-10-23 2014-07-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in companion animals
US8557846B1 (en) 2012-10-23 2013-10-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in dogs
US20140120121A1 (en) * 2012-10-30 2014-05-01 Bridge Pharma, Inc. Medicinal treatment of atopic inflammatory diseases
US20150272941A1 (en) * 2012-10-30 2015-10-01 Bridge Pharma, Inc. Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
US9138431B2 (en) 2013-08-06 2015-09-22 Bridge Pharma, Inc. Methods of treatment of histamine H-4 receptor-related pruritus
US9439895B2 (en) * 2013-08-06 2016-09-13 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients
US9345697B2 (en) * 2013-08-06 2016-05-24 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus
CN104059056B (zh) * 2014-06-26 2017-08-25 福建省闽东力捷迅药业有限公司 一种富马酸卢帕替芬晶型b及其制备方法
CA2988564C (en) * 2015-06-11 2021-10-05 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus in mammals
US9694003B2 (en) 2015-10-15 2017-07-04 Bridge Pharma, Inc. Formulations and methods for treating high intraocular pressure
CN106243096B (zh) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
AU2017325010A1 (en) 2016-09-08 2019-03-28 Emergo Therapeutics, Inc. Mast cell stabilizers for treatment of hypercytokinemia and viral infection
JP2019533018A (ja) 2016-10-18 2019-11-14 エマーゴ セラピューティクス,インク. 慢性炎症状態の処置の為の肥満細胞安定剤
US10959992B2 (en) 2019-02-22 2021-03-30 Bridge Pharma Inc. Methods of treatment of asthma and COPD
US20200268734A1 (en) * 2019-02-22 2020-08-27 Bridge Pharma, Inc. Methods of treatment of respiratory disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1089483A (en) 1964-02-04 1967-11-01 Sandoz Ltd Improvements in or relating to 4h-benzo(4,5)cyclohepta (1,2-b) thiophene derivatives
FR1447527A (fr) 1964-08-11 1966-07-29 Sandoz Sa Nouveaux benzo-cyclohepta-thiophènes et leur préparation
CH531000A (de) * 1970-03-11 1972-11-30 Sandoz Ag Verfahren zur Herstellung neuer Benzocycloheptathiophene
BE794377A (fr) * 1972-01-24 1973-07-23 Sandoz Sa Nouveaux derives du benzo-cyclohepta-thiophene
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
US4073915A (en) 1975-05-20 1978-02-14 Sandoz Ltd. Treating asthma
US4128549A (en) 1976-02-27 1978-12-05 Sandoz Ltd. Precursors of 4-(1-alkyl-4-piperidylidene-4H-benzo[4,5]cyclohepta-[1,2-b]thiophen-10(9H)-ones
CS263993B1 (cs) 1988-03-11 1989-05-12 Polivka Zdenek Způsob přípravy čistých enantiomerů 4- (l-meíhyl-4-piperidyliden) -4,9-dihydrobenzo [ 4,5) cyklohepta [ 1,2-b ] - thiofen-lQ-onu
EP0339978B1 (en) * 1988-04-28 1996-08-21 Schering Corporation Fused polycyclic compounds, compositions, methods of manufacture, and their use as PAF antagonists, antihistamines and/or antiinflammatory agents
GB9012926D0 (en) * 1990-06-09 1990-08-01 Scras Pyrrolo-pyridine derivatives
CA2093646A1 (en) * 1990-10-10 1992-04-11 Jesse K. Wong Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
CA2455115C (en) * 1991-12-12 2008-05-27 Glaxo Group Limited Pharmaceutical aerosol formulation
JP3342484B2 (ja) 1991-12-18 2002-11-11 アストラ・アクチエボラーグ 新規な配合
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
EP0977568B1 (en) * 1997-04-03 2006-03-08 Bridge Pharma, Inc. Benzocycloheptathiophene compounds
EP1014979A4 (en) * 1997-06-09 2003-08-20 Bridge Pharma Inc CONNECTIONS WITH COMBINED ANTIHISTAMINIC AND FAST-CELL STABILIZING ACTIVITY FOR OPHTHALMOLOGICAL USE
PL353586A1 (en) 1999-09-13 2003-12-01 Bridge Pharma, Inc.Bridge Pharma, Inc. Optically active isomers of ketotifen and therapeutically active metabolites thereof

Also Published As

Publication number Publication date
US7872025B2 (en) 2011-01-18
JP2003509369A (ja) 2003-03-11
IL148368A (en) 2007-10-31
EP1218007A1 (en) 2002-07-03
EP1218007B1 (en) 2011-07-20
PT1218007E (pt) 2011-10-27
PL353586A1 (en) 2003-12-01
ATE516804T1 (de) 2011-08-15
HUP0202671A3 (en) 2005-01-28
IL148368A0 (en) 2002-09-12
CA2383222C (en) 2008-11-18
EP1218007A4 (en) 2003-04-09
WO2001019367A1 (en) 2001-03-22
CA2383222A1 (en) 2001-03-22
BR0013935A (pt) 2002-05-14
US7226934B1 (en) 2007-06-05
MXPA02002658A (es) 2002-10-23
HUP0202671A2 (hu) 2002-11-28
US7557128B2 (en) 2009-07-07
DK1218007T3 (da) 2011-11-07
US20080287498A1 (en) 2008-11-20
AU7701400A (en) 2001-04-17
CY1112605T1 (el) 2016-02-10
CN1391475A (zh) 2003-01-15
JP5116928B2 (ja) 2013-01-09
AU782816B2 (en) 2005-09-01
US20090149502A1 (en) 2009-06-11
MY134888A (en) 2007-12-31

Similar Documents

Publication Publication Date Title
AR034396A1 (es) Compuestos 4-(1r-4-piperidilen)-4h-benzo[4,5]ciclohepta[1,2]-tiofeno-1-a y sus isomeros opticamente activos, un metodo para su sintesis y el uso de dichos compuestos para la manufactura de un medicamento
UY27092A1 (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
EA200700232A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
CL2004000174A1 (es) Compuestos derivados de malonamida n,n'-disustituidos; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de la enfermedad de alzheimer.
PA8491501A1 (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
MX9203444A (es) Medicamentos.
CO5670327A2 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion
UY28011A1 (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
ES2495965T3 (es) Uso de derivados 2,5-dihidroxibencénicos para el tratamiento de enfermedades oculares
CY1110450T1 (el) Χρησιμοποιηση ενος παραγωγου αλογονιδιου υδροξιμικου οξεος στη θεραπευτικη αγωγη νευροεκφυλιστικων νοσων
AR015448A1 (es) COMBINACIoN DE UN INHIBIDOR DE REABSORCIoN DE 5-HT CON UN ANTAGONISTA O AGONISTA PARCIAL DE H5-HT1B, PROCESO PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA QUE LA CONTIENE, SU USO PARA PREPARAR MEDICAMENTOS PARA TRATAR TRASTORNOS AFECTIVOS Y KIT QUE CONTIENE DICHA COMBINACIoN
AR013079A1 (es) Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
UY27018A1 (es) Derivados de la pirimidina
AR028475A1 (es) Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser
AR029588A1 (es) Nueva forma (r)-n-[5-metil-8-(4-metilpiperazina-1-il)-1,2,3,4-tetrahidro-2-naftil]-4-morfolinobenzamida
AR044869A1 (es) Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, su uso para fabricar un medicamento y procedimiento para su preparacion
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
CO4480025A1 (es) Nuevos usos de ciertos derivados del indol en el tratamiento o profilaxis de trastornos medicos
AR019322A1 (es) Derivados de sulfonilo sustituido por heterociclo-etanodionanilina sustituida por heterociclo, composicion farmaceutica que los contiene y su uso para lamanufactura de un medicamento
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
AR033779A1 (es) Compuestos utiles en la enfermedad de reflujo

Legal Events

Date Code Title Description
FC Refusal